Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model - PubMed
5 hours ago
- #Blinatumomab
- #Immunotherapy
- #Graft-versus-host disease
- Blinatumomab (BLINA) maintains antileukemic activity even when combined with abatacept (ABATA), which blocks CD28 to prevent graft-versus-host disease (GvHD).
- In vitro, ABATA did not reduce BLINA-induced T-cell cytotoxicity, degranulation, cytokine production, or activation against leukemia cell lines.
- In a mouse model of B-cell acute lymphoblastic leukemia (B-ALL), BLINA alone reduced tumor burden but caused severe GvHD and early death.
- Combining BLINA and ABATA preserved strong anti-leukemia effects while significantly reducing GvHD and extending survival by 35 days compared to controls.
- The study suggests BLINA can bypass CD28 blockade to sustain T-cell killing, offering a strategy to separate graft-versus-leukemia (GvL) from GvHD after transplantation.